Jennie-O recalling ground turkey in salmonella outbreak
Regulators say additional products from other companies could be named as their investigation continues.
Health Care
Articles
Eli Lilly considering sale of China assets to raise cash
Indianapolis-based Lilly is working with advisers to gauge interest in selling off a selection of older drugs for antibiotics and central nervous system diseases in China.
Two IU researchers win $2.3M grant to study neuropathy in cancer patients
The researchers are testing the effectiveness of a small, targeted molecule to prevent or reverse chemotherapy-induced peripheral neuropathy—a nerve problem that causes pain, numbness and tingling.
E-cigarettes facing new sales restrictions from FDA
New limitations will be placed on e-cigarettes, according to a senior FDA official, restricting sales of many popular fruit flavors amid what the health agency has called an epidemic of youth use.
Lilly raises guidance after topping profit, revenue expectations
Lilly’s revenue in the United States rose 11 percent year-over-year, to $3.4 billion, thanks largely to rising sales of diabetes drugs Trulicity and Basgalar, cancer treatment Verzenio and psoriasis medication Taltz.
Endocyte insiders to reap millions from Novartis deal
Executives and directors of the West Lafayette-based biotech hold nearly 9 percent of Endocyte stock, worth about $177 million, based on the deal price of $24 a share.
Hamilton County officials debate 10 percent income tax hike for 911
For at least a year, county officials have debated how best to pay for the county’s 911 communications operation going forward.
Eli Lilly partner urges investors to look beyond biotech turmoil
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
Obamacare markets stabilize, but premiums remain high for many
On average, the premium for typical plans in the 39 states that use the federal healthcare.gov website will drop 1.5 percent.
Tobacco, opioid epidemics claimed 14,200 Hoosier lives in 2017, studies say
Two reports, sponsored by the Richard M. Fairbanks Foundation, say the state should not let up in fighting twin scourges that claim thousands of lives and cost billions of dollars in health care costs and lost productivity.
Shoppers may face hard choices again on health marketplaces
Much of the insurance left on the Affordable Care Act marketplaces limits patients to narrow networks of hospitals or doctors and provides no coverage outside those networks.
Trump says new proposal will slash some U.S. drug prices
President Donald Trump said he was “taking aim at the global freeloading that forces American consumers to subsidize lower prices in foreign countries through higher prices in our country.”
Trump focusing on drug prices, high among voters’ concerns
President Donald Trump is linking the drug prices Americans complain about to one of his longstanding grievances: foreign countries the president says are taking advantage of U.S. research breakthroughs.
IU Health covets big prize, but neurosurgery practice clings to independence
Indiana University Health Physicians is setting its sights on one of the state’s last independent specialty holdouts, the neurosurgical Goodman Campbell Brain and Spine.
Purdue delays health care changes for employees’ spouses
The plan approved by Purdue trustees on Oct. 12 met widespread opposition from faculty and staff.
Opioid alternative from Lilly, Pfizer shows promise in study
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
Novartis needs U.S. security nod for Endocyte under new rules
The Treasury pilot program implements broader powers Congress granted this year to the Committee on Foreign Investment in the U.S., a panel of officials who review foreign takeover of American firms and can recommend that the president block deals that threaten national security.
Endocyte’s $2.1B deal with Novartis comes after years of setbacks
The West Lafayette biotech firm’s stock traded as low as $1.41 last fall, following multiple setbacks and restructurings. But the stock had soared to $24 Thursday morning after news that it would be acquired by Novartis.
Endocyte acquisition gives Novartis key therapy—at almost 200 times its last price
One year ago, Indiana-based Endocyte Inc. bought the rights to a prostate cancer treatment for $12 million, plus future considerations. On Thursday, Novartis AG agreed to pay almost 200 times that amount to acquire Endocyte and the experimental therapy.
Firm planning $25M behavioral health hospital in Plainfield
The standalone, two-story facility is expected to offer a wide array of inpatient and outpatient services, including addiction treatment, counseling and psychiatric intensive care.